Biotech | May 06, 2022
Procter & Gamble Health posts 14 per cent growth in net profit in Q3
The increase in PAT is driven by higher sales and lower marketing and depreciation charge vs the same period last year
The increase in PAT is driven by higher sales and lower marketing and depreciation charge vs the same period last year
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
South Carolina’s largest health system adopts Philips software solutions for patient monitoring and enterprise imaging, helping to drive interoperability and data analytics, and deliver on Quadruple Aim
The management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years
Beyond the technical leadership from F1, the collaboration will bring a specific focus on the people dimension of high performance
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Subscribe To Our Newsletter & Stay Updated
